Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

103 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry is designed to monitor the real world clinical performance and safety of the V8 device used to perform balloon aortic valvuloplasty (BAV). Additional analyses or calculations may be obtained from the imaging or evaluations already performed per the sites' standard of care

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Balloon Aortic Valvuloplasty

NCT02122900

Aortic Stenosis

COMPLETED

Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation

NCT02847546

Aortic Valve Stenosis

COMPLETED

The VIRTUE Post Marketing Surveillance Registry

NCT01213589

Aortic Dissection

COMPLETED

Balloon-Expandable Versus Self-expanding Transcatheter Heart Valve for Treatment of Symptomatic Native Aortic Valve Stenosis (BEST)

NCT05454150

Aortic Valve Stenosis

ACTIVE_NOT_RECRUITING NA

Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms

NCT03246126

Thoracoabdominal Aortic Aneurysms

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is an open-label observational study involving a minimum of 10 centers. A minimum of 100 patients, including a minimum of 30 stand-alone balloon aortic valvuloplasty (BAV) treatment patients, will be enrolled. Enrollment will continue until all 3 of these conditions are met.

BAV-only patients will be followed through a 6-month post-treatment telephone follow up. Patients treated with the V8 device for BAV as a bridge to transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) or as an intraprocedural predilatation prior to TAVR, will exit the study at the time of the TAVR or SAVR implant or at 6 months post-BAV treatment, whichever comes first.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

V8 Balloon Aortic Valvuloplasty (BAV) Catheter

The V8 device can be used for BAV as follows:

* as stand-alone intervention
* as a bridge to transcatheter aortic valve replacement (TAVR)
* as a bridge to surgical aortic valve replacement (SAVR)
* as an intraprocedural predilatation prior to TAVR

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic severe aortic stenosis (AS) patients who are not suitable candidates for aortic valve replacement surgery at the time of BAV procedure.
* Subject meets the Indication For Use.
* Probable survival to hospital discharge.
* Subject is competent, willing to comply with evaluations, understands risks, benefits and alternatives and has signed the Informed Consent Form. Alternatively, the legal guardian of the patient is able to give consent to participate.

Exclusion Criteria

* Patient has undergone previous AVR
* Greater or equal to 3+ aortic insufficiency by echocardiogram obtained prior to planned BAV or intra-procedural predilation TAVR procedure
* Non-valvular AS
* Known congenital AV abnormality (e.g., bicuspid AV)
* Cardiogenic shock, as defined by a consistent systolic blood pressure \<80 mmHg off vasopressors or \<90 mmHg on vasopressors.
* Bacterial endocarditis ≤ 12 months prior to planned BAV procedure
* Unable to take aspirin (acetyl salicylic acid, ASA) or thienopyridine
* Any illness or condition which, in the Investigator's judgment, will compromise patient safety, or interfere with the interpretation of the treatment results
* Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

Eligible Sex

ALL

Accepts Healthy Volunteers

No